Johnson & Johnson EPS - Earnings per Share 1986-2025 | JNJ

Johnson & Johnson annual and quarterly earnings per share history from 1986 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Johnson & Johnson EPS for the quarter ending June 30, 2025 was $2.29, a 18.65% increase year-over-year.
  • Johnson & Johnson EPS for the twelve months ending June 30, 2025 was $9.35, a 37.92% decline year-over-year.
  • Johnson & Johnson 2024 annual EPS was $5.79, a 57.8% decline from 2023.
  • Johnson & Johnson 2023 annual EPS was $13.72, a 103.86% increase from 2022.
  • Johnson & Johnson 2022 annual EPS was $6.73, a 13.83% decline from 2021.
Johnson & Johnson Annual EPS
2024 $5.79
2023 $13.72
2022 $6.73
2021 $7.81
2020 $5.51
2019 $5.63
2018 $5.61
2017 $0.47
2016 $5.93
2015 $5.48
2014 $5.70
2013 $4.81
2012 $3.86
2011 $3.49
2010 $4.78
2009 $4.40
2008 $4.57
2007 $3.63
2006 $3.73
2005 $3.35
2004 $2.74
2003 $2.40
2002 $2.16
2001 $1.84
2000 $1.61
1999 $1.39
1998 $1.06
1997 $1.21
1996 $1.06
1995 $0.93
1994 $0.78
1993 $0.69
1992 $0.39
1991 $0.27
1990 $0.43
1989 $0.41
1988 $0.18
1987 $0.27
1986 $0.11
1985 $0.21
Johnson & Johnson Quarterly EPS
2025-06-30 $2.29
2025-03-31 $4.54
2024-12-31 $1.41
2024-09-30 $1.11
2024-06-30 $1.93
2024-03-31 $1.34
2023-12-31 $1.58
2023-09-30 $10.21
2023-06-30 $1.96
2023-03-31 $-0.03
2022-12-31 $1.32
2022-09-30 $1.68
2022-06-30 $1.80
2022-03-31 $1.93
2021-12-31 $1.77
2021-09-30 $1.37
2021-06-30 $2.35
2021-03-31 $2.32
2020-12-31 $0.65
2020-09-30 $1.33
2020-06-30 $1.36
2020-03-31 $2.17
2019-12-31 $1.50
2019-09-30 $0.66
2019-06-30 $2.08
2019-03-31 $1.39
2018-12-31 $1.12
2018-09-30 $1.44
2018-06-30 $1.45
2018-03-31 $1.60
2017-12-31 $-3.91
2017-09-30 $1.37
2017-06-30 $1.40
2017-03-31 $1.61
2016-12-31 $1.38
2016-09-30 $1.53
2016-06-30 $1.43
2016-03-31 $1.59
2015-12-31 $1.14
2015-09-30 $1.20
2015-06-30 $1.61
2015-03-31 $1.53
2014-12-31 $0.89
2014-09-30 $1.66
2014-06-30 $1.51
2014-03-31 $1.64
2013-12-31 $1.22
2013-09-30 $1.04
2013-06-30 $1.33
2013-03-31 $1.22
2012-12-31 $0.90
2012-09-30 $1.05
2012-06-30 $0.50
2012-03-31 $1.41
2011-12-31 $0.09
2011-09-30 $1.15
2011-06-30 $1.00
2011-03-31 $1.25
2010-12-31 $0.70
2010-09-30 $1.23
2010-06-30 $1.23
2010-03-31 $1.62
2009-12-31 $0.79
2009-09-30 $1.20
2009-06-30 $1.15
2009-03-31 $1.26
2008-12-31 $0.97
2008-09-30 $1.17
2008-06-30 $1.17
2008-03-31 $1.26
2007-12-31 $0.82
2007-09-30 $0.88
2007-06-30 $1.05
2007-03-31 $0.88
2006-12-31 $0.74
2006-09-30 $0.94
2006-06-30 $0.95
2006-03-31 $1.10
2005-12-31 $0.70
2005-09-30 $0.85
2005-06-30 $0.86
2005-03-31 $0.94
2004-12-31 $0.31
2004-09-30 $0.78
2004-06-30 $0.82
2004-03-31 $0.83
2003-12-31 $0.62
2003-09-30 $0.69
2003-06-30 $0.40
2003-03-31 $0.69
2002-12-31 $0.46
2002-09-30 $0.57
2002-06-30 $0.54
2002-03-31 $0.59
2001-12-31 $0.37
2001-09-30 $0.49
2001-06-30 $0.48
2001-03-31 $0.50
2000-12-31 $0.32
2000-09-30 $0.43
2000-06-30 $0.44
2000-03-31 $0.47
1999-12-31 $0.27
1999-09-30 $0.39
1999-06-30 $0.41
1999-03-31 $0.40
1998-12-31 $0.04
1998-09-30 $0.34
1998-06-30 $0.36
1998-03-31 $0.33
1997-12-31 $0.23
1997-09-30 $0.32
1997-06-30 $0.34
1997-03-31 $0.33
1996-12-31 $0.21
1996-09-30 $0.28
1996-06-30 $0.29
1996-03-31 $0.29
1995-12-31 $0.18
1995-09-30 $0.24
1995-06-30 $0.26
1995-03-31 $0.26
1994-12-31 $0.15
1994-09-30 $0.21
1994-06-30 $0.22
1994-03-31 $0.21
1993-12-31 $0.13
1993-09-30 $0.18
1993-06-30 $0.19
1993-03-31 $0.19
1992-12-31 $0.12
1992-09-30 $0.16
1992-06-30 $0.17
1992-03-31 $0.18
1991-12-31 $0.05
1991-09-30 $0.14
1991-06-30 $0.15
1991-03-31 $0.16
1990-12-31 $0.09
1990-09-30 $0.12
1990-06-30 $0.13
1990-03-31 $0.09
1989-12-31 $0.08
1989-09-30 $0.10
1989-06-30 $0.11
1989-03-31 $0.10
1988-12-31 $0.04
1988-09-30 $0.09
1988-06-30 $0.10
1988-03-31 $0.10
1987-12-31 $0.05
1987-09-30 $0.08
1987-06-30 $0.08
1987-03-31 $0.09
1986-12-31 $0.00
1985-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $450.090B $94.943B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12